MX2023000738A - Proteinas de union a antigeno que activan el receptor de leptina. - Google Patents
Proteinas de union a antigeno que activan el receptor de leptina.Info
- Publication number
- MX2023000738A MX2023000738A MX2023000738A MX2023000738A MX2023000738A MX 2023000738 A MX2023000738 A MX 2023000738A MX 2023000738 A MX2023000738 A MX 2023000738A MX 2023000738 A MX2023000738 A MX 2023000738A MX 2023000738 A MX2023000738 A MX 2023000738A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen
- lepr
- binding fragments
- leptin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen al receptor de leptina (LEPR), y métodos de uso de los mismos. De acuerdo con ciertas formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR y activan la señalización de LEPR. En otras formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR y potencian la sensibilización de LEPR a un antígeno. En ciertas formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR en presencia y ausencia de leptina. En ciertas formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que inducen la señalización en células que expresan mutantes de LEPR que de otro modo exhiben una señalización deficiente o disminuida en presencia de leptina. Los anticuerpos y fragmentos de unión a antígeno de la presente invención son útiles para el tratamiento de las lipodistrofias y otras enfermedades y trastornos asociados o causados por la deficiencia de leptina o la resistencia a la leptina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240021P | 2015-10-12 | 2015-10-12 | |
| US201662359757P | 2016-07-08 | 2016-07-08 | |
| US201662375495P | 2016-08-16 | 2016-08-16 | |
| US201662393143P | 2016-09-12 | 2016-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000738A true MX2023000738A (es) | 2023-02-13 |
Family
ID=57184864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004531A MX2018004531A (es) | 2015-10-12 | 2016-10-11 | Proteinas de union a antigeno que activan el receptor de leptina. |
| MX2023000738A MX2023000738A (es) | 2015-10-12 | 2018-04-12 | Proteinas de union a antigeno que activan el receptor de leptina. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004531A MX2018004531A (es) | 2015-10-12 | 2016-10-11 | Proteinas de union a antigeno que activan el receptor de leptina. |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US10023644B2 (es) |
| EP (2) | EP3362477B1 (es) |
| JP (5) | JP7034068B2 (es) |
| KR (2) | KR20250069979A (es) |
| CN (1) | CN108368177B (es) |
| AU (2) | AU2016338851B2 (es) |
| BR (1) | BR112018007318A2 (es) |
| CA (1) | CA3000215A1 (es) |
| CL (2) | CL2018000946A1 (es) |
| CO (1) | CO2018003852A2 (es) |
| CY (1) | CY1125102T1 (es) |
| DK (1) | DK3362477T3 (es) |
| EA (1) | EA201890928A1 (es) |
| ES (1) | ES2908574T3 (es) |
| HR (1) | HRP20220426T8 (es) |
| HU (1) | HUE058280T2 (es) |
| IL (3) | IL316563A (es) |
| LT (1) | LT3362477T (es) |
| MX (2) | MX2018004531A (es) |
| MY (1) | MY187975A (es) |
| PH (1) | PH12018500663A1 (es) |
| PL (1) | PL3362477T3 (es) |
| PT (1) | PT3362477T (es) |
| RS (1) | RS63061B1 (es) |
| SG (1) | SG10201913432RA (es) |
| SI (1) | SI3362477T1 (es) |
| SM (1) | SMT202200125T1 (es) |
| TW (3) | TWI824372B (es) |
| UA (1) | UA124419C2 (es) |
| UY (1) | UY36942A (es) |
| WO (1) | WO2017066204A1 (es) |
| ZA (1) | ZA201801975B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295010B2 (en) | 2015-03-10 | 2025-10-01 | Regeneron Pharma | Pollution-free piercing system and method |
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) * | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
| US11547801B2 (en) | 2017-05-05 | 2023-01-10 | Regeneron Pharmaceuticals, Inc. | Auto-injector |
| MX2020006508A (es) | 2017-12-18 | 2020-09-17 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. |
| DK3773713T3 (da) | 2018-04-06 | 2025-08-18 | Regeneron Pharma | Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI |
| JP7328982B2 (ja) * | 2018-10-11 | 2023-08-17 | 住友化学株式会社 | プロピレンオキサイド精製装置、及び、プロピレンオキサイドの製造方法 |
| EP3918326A4 (en) * | 2019-01-31 | 2022-04-20 | Siemens Healthcare Diagnostics, Inc. | ANTI-NALOXONE AND ANTI-NALTREXONE MONOCLONAL ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| GB2600273B (en) * | 2019-07-02 | 2024-06-05 | Univ Shanghai Technology | Antibody to leptin receptor |
| CN114746848B (zh) | 2019-12-03 | 2023-08-04 | 美光科技公司 | 用于存储装置的高速缓存架构 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CA3192156A1 (en) * | 2020-09-15 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Use of lepr agonists for pain |
| LT4294257T (lt) | 2021-02-22 | 2025-12-29 | Regeneron Pharmaceuticals, Inc. | Dalinės lipodistrofijos diagnostikos ir gydymo būdas |
| CN114456124B (zh) * | 2021-12-30 | 2023-04-21 | 华南农业大学 | 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用 |
| TW202515628A (zh) | 2023-06-16 | 2025-04-16 | 美商再生元醫藥公司 | 醫療裝置包裝及相關方法 |
| WO2025075970A1 (en) | 2023-10-02 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Drug delivery device safety system |
| JP2025148269A (ja) | 2024-03-15 | 2025-10-07 | イーライ リリー アンド カンパニー | 肥満を治療するための単独又は併用療法としてのレプチン受容体アゴニスト抗体 |
| WO2025227054A1 (en) * | 2024-04-25 | 2025-10-30 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies binding to leptin and uses thereof |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| EP1619250B1 (en) | 1996-01-08 | 2009-11-25 | Genentech, Inc. | OB receptor variant and ligands |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| ES2260784T3 (es) | 1996-01-23 | 2006-11-01 | Indevus Pharmaceuticals, Inc. | Metodos de utilizacion del gen obese y su producto genico para estimular el desarrolo hematopoyetico. |
| AUPN780096A0 (en) * | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| SI2219031T1 (sl) | 2001-10-22 | 2013-11-29 | Amgen, Inc. | Uporaba leptina za zdravljenje lipoatrofije pri ljudeh in metoda za ugotavljanje dovzetnosti za navedeno zdravljenje |
| EP2002827A2 (en) * | 2001-12-05 | 2008-12-17 | The Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| DE10353593A1 (de) | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| WO2005056602A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| WO2006053883A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Fibronectin iii domain as leptin receptor antagonists |
| CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| WO2009045900A2 (en) | 2007-09-28 | 2009-04-09 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing diseases associated with low bone mass |
| JP2012508017A (ja) | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | 抗ｄｌｌ４抗体及びその使用 |
| DK2564695T3 (en) | 2009-07-08 | 2015-05-26 | Kymab Ltd | Animal models and therapeutic molecules |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| PL2505654T5 (pl) | 2010-02-08 | 2020-11-30 | Regeneron Pharmaceuticals, Inc. | Mysz ze wspólnym łańcuchem lekkim |
| PH12013500974A1 (en) | 2010-11-17 | 2013-07-08 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| CN103476433A (zh) | 2011-02-10 | 2013-12-25 | 罗切格利卡特公司 | 改良的免疫疗法 |
| LT2578688T (lt) | 2011-02-25 | 2019-11-11 | Regeneron Pharma | Adam6 pelės |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013022782A1 (en) | 2011-08-05 | 2013-02-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| MX2014014891A (es) | 2012-06-05 | 2015-06-17 | Regeneron Pharma | Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun. |
| FI3366705T3 (fi) | 2012-09-12 | 2023-07-28 | Genzyme Corp | Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| JP6666848B2 (ja) | 2014-02-18 | 2020-03-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｎｒｐ−１／ｏｂｒ複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物 |
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
| CN107760761A (zh) | 2017-11-10 | 2018-03-06 | 江苏省农业科学院 | 一种加强瘦素激发lepr信号转导的方法 |
| MX2020006508A (es) | 2017-12-18 | 2020-09-17 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. |
| DK3773713T3 (da) | 2018-04-06 | 2025-08-18 | Regeneron Pharma | Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI |
-
2016
- 2016-10-07 TW TW111100429A patent/TWI824372B/zh active
- 2016-10-07 TW TW105132493A patent/TWI752920B/zh active
- 2016-10-07 TW TW112125041A patent/TW202417497A/zh unknown
- 2016-10-11 UY UY0001036942A patent/UY36942A/es not_active Application Discontinuation
- 2016-10-11 SI SI201631477T patent/SI3362477T1/sl unknown
- 2016-10-11 PT PT167850726T patent/PT3362477T/pt unknown
- 2016-10-11 WO PCT/US2016/056465 patent/WO2017066204A1/en not_active Ceased
- 2016-10-11 JP JP2018518592A patent/JP7034068B2/ja active Active
- 2016-10-11 HR HRP20220426TT patent/HRP20220426T8/hr unknown
- 2016-10-11 RS RS20220294A patent/RS63061B1/sr unknown
- 2016-10-11 KR KR1020257014408A patent/KR20250069979A/ko active Pending
- 2016-10-11 BR BR112018007318-0A patent/BR112018007318A2/en active IP Right Grant
- 2016-10-11 EP EP16785072.6A patent/EP3362477B1/en active Active
- 2016-10-11 MX MX2018004531A patent/MX2018004531A/es unknown
- 2016-10-11 CN CN201680072173.1A patent/CN108368177B/zh active Active
- 2016-10-11 DK DK16785072.6T patent/DK3362477T3/da active
- 2016-10-11 AU AU2016338851A patent/AU2016338851B2/en active Active
- 2016-10-11 SM SM20220125T patent/SMT202200125T1/it unknown
- 2016-10-11 KR KR1020187013185A patent/KR20180070609A/ko not_active Ceased
- 2016-10-11 HU HUE16785072A patent/HUE058280T2/hu unknown
- 2016-10-11 LT LTEPPCT/US2016/056465T patent/LT3362477T/lt unknown
- 2016-10-11 SG SG10201913432RA patent/SG10201913432RA/en unknown
- 2016-10-11 US US15/290,967 patent/US10023644B2/en active Active
- 2016-10-11 IL IL316563A patent/IL316563A/en unknown
- 2016-10-11 EA EA201890928A patent/EA201890928A1/ru unknown
- 2016-10-11 MY MYPI2018701183A patent/MY187975A/en unknown
- 2016-10-11 CA CA3000215A patent/CA3000215A1/en active Pending
- 2016-10-11 ES ES16785072T patent/ES2908574T3/es active Active
- 2016-10-11 UA UAA201803447A patent/UA124419C2/uk unknown
- 2016-10-11 EP EP21207469.4A patent/EP4071173A1/en active Pending
- 2016-10-11 PL PL16785072T patent/PL3362477T3/pl unknown
- 2016-10-11 IL IL300961A patent/IL300961B2/en unknown
-
2018
- 2018-03-26 PH PH12018500663A patent/PH12018500663A1/en unknown
- 2018-03-26 ZA ZA2018/01975A patent/ZA201801975B/en unknown
- 2018-03-29 IL IL258448A patent/IL258448B2/en unknown
- 2018-04-11 CO CONC2018/0003852A patent/CO2018003852A2/es unknown
- 2018-04-12 CL CL2018000946A patent/CL2018000946A1/es unknown
- 2018-04-12 MX MX2023000738A patent/MX2023000738A/es unknown
- 2018-06-13 US US16/007,848 patent/US10253102B2/en active Active
- 2018-06-13 US US16/007,812 patent/US10618968B2/en active Active
-
2019
- 2019-05-28 CL CL2019001434A patent/CL2019001434A1/es unknown
- 2019-10-04 US US16/593,761 patent/US20200031946A1/en not_active Abandoned
-
2021
- 2021-03-11 JP JP2021039405A patent/JP7165225B2/ja active Active
- 2021-11-30 US US17/539,034 patent/US12275792B2/en active Active
-
2022
- 2022-03-31 CY CY20221100249T patent/CY1125102T1/el unknown
- 2022-10-21 JP JP2022169008A patent/JP7436603B2/ja active Active
-
2023
- 2023-07-19 AU AU2023206125A patent/AU2023206125A1/en active Pending
- 2023-11-30 JP JP2023202680A patent/JP7699191B2/ja active Active
-
2024
- 2024-02-09 JP JP2024018406A patent/JP7759417B2/ja active Active
- 2024-08-20 US US18/810,454 patent/US20250051465A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| SA518400222B1 (ar) | أجسام مضادة لـ وتركيبات tim-3 | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
| PH12016500943A1 (en) | Aplnr modulatros and uses thereof | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| MX386942B (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| CR20170351A (es) | Proteínas de unión a icos | |
| AU2018230657A8 (en) | Anti-C5 antibodies and uses thereof | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| WO2018148486A8 (en) | Anti-factor d antibodies and uses thereof | |
| UA123202C2 (uk) | Антитіло до тау-білка і його застосування | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| EA201900562A1 (ru) | Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты | |
| EA201892063A1 (ru) | МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
| PH12019500342A1 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
| MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. |